<code id='CBA4E12243'></code><style id='CBA4E12243'></style>
      • <acronym id='CBA4E12243'></acronym>
      <center id='CBA4E12243'><center id='CBA4E12243'><tfoot id='CBA4E12243'></tfoot></center><abbr id='CBA4E12243'><dir id='CBA4E12243'><tfoot id='CBA4E12243'></tfoot><noframes id='CBA4E12243'>
      • <optgroup id='CBA4E12243'><strike id='CBA4E12243'><sup id='CBA4E12243'></sup></strike><code id='CBA4E12243'></code></optgroup>
        5. <b id='CBA4E12243'><label id='CBA4E12243'><select id='CBA4E12243'><dt id='CBA4E12243'><span id='CBA4E12243'></span></dt></select></label></b><u id='CBA4E12243'></u>
          <i id='CBA4E12243'><strike id='CBA4E12243'><tt id='CBA4E12243'><pre id='CBA4E12243'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / fashion / hotspot      
           
     
           
      
          hotspot 
           
      
           
      
           
       2025-10-06 07:17:37 
   
      
           
      
           
                        
          hotspot  
          
                                   
                 
                                      author：entertainment   
                                        
                                      
                                      Page View：9793
                                  
                                    
          
                                   
          Adam's take main illustration
          Molly Ferguson/STAT
          Biotech is awash in PIPEs.
          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.
          advertisement
          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          3 hurdles to bringing medical devices to the U.S. market
                                
                            
          Next article：  
                                      
                                          DIEP, the 'gold standard' of breast reconstruction, is under threat
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles